Medicon Valley Biomedical Newsletter

7TM Pharma A/S announces that the company has been granted patents in the UK covering the use of the drug candidates Obinepitide and TM30339, both for the treatment of obesity. Obinep...

ACADIA Pharmaceuticals Inc. has announced the initiation of a Phase IIb clinical trial designed to evaluate the safety and efficacy of ACP-104 as a treatment for patients with schizophrenia. Th...

The European Patent Organisation has granted a patent to Bavarian Nordic A/S which further strengthens its intellectual property position on Modified vaccinia virus Ankara, MVA, in Europe. The ...

BioGaia AB has reached an agreement with BioLife New Zealand Ltd. giving BioLife the rights to sell BioGaia´s newly-developed sachet, potion packs, containing colostrum and Reuteri, in China. C...

BoneSupport AB is establishing a subsidiary in North America. The Lund-based company wants to strengthen its business in the important and strategic U.S. market. At the same time, the company reports ...

CellaVision AB pre-launches a new application for analysis of body fluids at the international trade convention AACC in California, USA. The application is optimized for analysis of cerebrospinal flui...

Genmab A/S announced that it has regained all rights to the HuMax-CD4, zanolimumab, antibody from Merck Serono S.A. Genmab plans to continue moving development of HuMax-CD4 forward in the existing non...

LEO Pharma A/S has submitted a New Drug Application to the FDA for a topical gel for the treatment of scalp psoriasis. In the U.S. the drug will be called Taclonex Scalp gel. At the same ...

LifeCycle Pharma A/S has announced the initiation of a Phase II clinical trial program using LCP-AtorFen, a fixed-dose combination of atorvastatin and fenofibrate, for the treatment of high cholestero...

At Lund University changes have been made regarding innovation activity according to strategic plans. It has been decided to expand and strengthen the innovation activity at the university. LU Innovat...

Maxygen, Inc. has announced the initiation of a phase IIa trial to evaluate the efficacy, safety and tolerability of MAXY-G34 in the treatment of chemotherapy-induced neutropenia. MAXY-G34 is a novel ...

MediCult A/S has successfully demonstrated that its proprietary Synthetic Serum Replacement, SSR, Media supports the growth of adult stem cells, mesenchymal stem cells. The proof of concept study show...

Novo Nordisk is taking the lead in communicating with the public through the launch of two new websites dedicated to clinical trials and bioethics, respectively. Both sites are aimed at a wide target ...

Novozymes A/S has signed a definitive agreement under which it will acquire the enzyme activities of Biocon Limited, Bangalore, India. Novozymes does not currently hold any stake in Biocon. The total ...

Nycomed A/S and its partner NPS Pharmaceuticals have announced that they have entered an agreement expanding and amending rights and responsibilities under the Preotact license originally entered into...

Nycomed A/S has announced that its partner Neurim Pharmaceuticals EEC, the EU subsidiary of Neurim Pharmaceuticals Ltd, has received a European Marketing Authorisation for Circadin 2 mg, prolonged rel...

Santaris Pharma A/S has announced that the Danish National Advanced Technology Foundation, ATF, has awarded a grant of EUR 1.35 million towards the development of the first ever drug targeted against ...

TopoTarget A/S announces the completion of the acquisition of Apoxis SA with 3,598,030 shares having been issued to the vendors of Apoxis. Hereby TopoTarget gains two first-in-class oncology products ...

Zymenex A/S has initiated the Phase II part of the clinical trial with Metazym in seriously ill children with Metachromatic Leukodystrophy, MLD. The trial will hopefully show the way to a cure for the...